Skip to main content

Table 3 Response rate of epidermal growth factor receptor tyrosine kinase inhibitors according to mutation type

From: Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types

  CR PR SD PD p value
Total (n = 363) 1 (0.3) 265 (73.0) 72 (19.8) 25 (6.9)  
E19del (n = 175)      0.785
 Afatinib (n = 53) 0 38 (71.7) 12 (22.6) 3 (5.7)  
 Erlotinib (n = 69) 1 (1.4) 54 (78.3) 10 (14.5) 4 (5.8)  
 Gefitinib (n = 53) 0 40 (75.5) 11 (20.8) 2 (3.8)  
L858R (n = 154)      0.471
 Afatinib (n = 38) 0 30 (78.9) 6 (15.8) 2 (5.3)  
 Erlotinib (n = 61) 0 42 (68.9) 15 (24.6) 4 (6.6)  
 Gefitinib (n = 55) 0 45 (81.8) 9 (16.4) 1 (1.8)  
Uncommon (n = 34)      0.332
 Afatinib (n = 11) 0 6 (54.5) 3 (27.3) 2 (18.2)  
 Erlotinib (n = 9) 0 4 (44.4) 4 (44.4) 1 (11..1)  
 Gefitinib (n = 14) 0 6 (42.9) 2 (14.3) 6 (42.9)  
  1. Data are shown as n (%) per each group
  2. CR complete response, PR partial response, SD stable disease, PD progressive disease, E19del exon 19 deletion, L858R L858R point mutation, Uncommon uncommon mutations